Antisense appoints experienced biotech executive
Antisense Therapeutics Limited (ASX:ANP) announced on Thursday that it had appointed Gil Price M.D. as Consultant Medical Director.
Dr. Price is a clinical physician trained in internal medicine with a long-standing focus in drug development, adverse drug reactions, drug utilization and regulation.
He is an experienced biotech executive and entrepreneur with a depth of expertise across clinical asset investment strategy, evaluation, financing and execution.
Gil’s experience should be valuable in assisting Antisense Therapeutics given its position as an Australian publicly listed biopharmaceutical company, developing and commercialising antisense pharmaceuticals for large unmet markets.
The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ:IONS), world leaders in antisense drug development and commercialisation.
As a backdrop, one of its key products, ATL1102 (injection) has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS).
The company’s ATL1103 drug designed to block GHr production successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.
Antisense Therapeutics is also conducting a Phase II clinical trial of ATL1102 in DMD patients at the Royal Childrens Hospital, Melbourne.
Price transforms Sarepta Therapeutics to multi-billion dollar company
Over a lengthy period, Price has served on multiple boards of public, private and not-for-profit entities.
From 2007 to 2016, he was a non-executive director of Sarepta Therapeutics, Inc., where he helped guide the company’s transition from US$80 million market capitalisation (2008) to a multi-billion dollar group with the first approved drug for DMD now generating annual sales approaching US$400 million
Price’s initial focus will be on engaging with Key Opinion Leaders in the treatment of DMD, as well as DMD Patient Advocacy Groups to help increase the awareness of the company’s ATL1102 for DMD development program.
This will entail translating the features and benefits of the program to these audiences and to advocates internationally and in the capital markets.
Upon commencement of the company’s pivotal trial of ATL1102 in Europe, Price’s responsibilities will also include pharmacovigilance oversight, adverse event reporting and clinical safety monitoring.
Price has collegial support
Having worked with Price for more than eight years at Sarepta, William Goolsbee, non-executive director of Antisense Therapeutics said, “It is great news that Dr. Price has agreed to join our team.
‘’Accessing his deep understanding of DMD and his years of commercial development experience is a tremendous advance for our company.
‘’Gil's skill set, combining the views of a physician, the rigors of a clinical scientist, understanding of the Patient Advocacy community and experience in translating these things to the capital markets will be a huge assistance in bringing the ATL1102 to the US, the European Union and beyond.’’
Particularly with DMD, Antisense Therapeutics needs both scientific insight and a high sense of urgency to meet the unmet need of the boys and their families.
Price believes that Antisense has the opportunity to bring an unprecedented drug to treat DMD and possibly other diseases.
Importantly, the appointment further validates the company’s business prospects, and on this note managing Director Mark Diamond said, ‘’We see his appointment as a critical step for the company in broadening our international presence as we advance towards drug commercialisation.”
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.